Trial of WVE-004 in Patients With C9orf72 Mutations Begins Dosing

Trial of WVE-004 in Patients With C9orf72 Mutations Begins Dosing

300276

Trial of WVE-004 in Patients With C9orf72 Mutations Begins Dosing

Dosing has begun in a clinical trial of WVE-004, Wave Life Sciences‘ investigational therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) associated with C9orf72 gene mutations. “ALS and FTD are devastating illnesses where therapeutic progress has been extremely limited. Advancing discovery and development of new treatments … is an urgent need,” Michael Panzara, MD, MPH, chief medical officer of Wave Life Sciences, said in a press release. The Phase 1b/2a trial, called FOCUS-C9 (NCT04931862),…

You must be logged in to read/download the full post.